Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease

Abstract

Basiliximab appears to promote prolonged remission after a single treatment. Taken in combination with previously reported data, basiliximab shows particular promise in moderate steroid-resistant ulcerative colitis.